FTSE MIB
35.400,71 -9,42 (-0,03%) Dow Jones
39.897,83 +28,45 (+0,07%) Nasdaq
16.702,29 +3,97 (+0,02%) Nikkei 225
38.787,38 -132,88 (-0,34%) Petrolio
79,51 +0,28 (+0,35%) Bitcoin EUR
61.583,43 +1.171,29 (+1,94%)
Phathom Pharmaceuticals, Inc. (PHAT)
| Chiusura precedente | 10,69 |
| Aperto | 10,72 |
| Denaro | 10,43 x 200 |
| Lettera | 13,45 x 200 |
| Min-Max giorno | 10,46 - 10,73 |
| Intervallo di 52 settimane | 6,07 - 17,02 |
| Volume | |
| Media Volume | 802.319 |
| Capitalizzazione | 614,62M |
| Beta (5 anni mensile) | 0,67 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,46 |
| Prossima data utili | 08 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 22,88 |
GlobeNewswirePhathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile consistent with prior vonoprazan studiesNew drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for vonoprazan as a daily treatment for Non-Erosive GERD, the largest subcategory of GERD with an estimated U.S. adult population of 38 millionFDA action date for Non-Erosive GERD ND
- GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference in New York City. Management will participate in one-on-one meetings on September 12, 2023.H.C. Wainwright 2
- GlobeNewswire
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration (FDA) and continue to support the requested product shelf lifeSubmission of six-month stability data satisfies Phathom's stability data submission requirements for Erosive GERD New Drug Application (NDA) for vonoprazan with a Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023 FLORHAM PARK, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,
